Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bicycle Therapeutics Q3 2026 Results: Net Loss of $10.5M, Loss Narrows

Bicycle Therapeutics reported collaboration revenue of $34.1 million for the quarter ended September 30, 2026, a significant increase from $11.7 million in the prior year. The company reduced its quarterly net loss to $9.3 million compared to $58.9 million in 2025, primarily driven by higher revenue and a decrease in research and development expenses following a strategic reprioritization.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue34.111.7
Profit before tax-9.3-58.9
Net income-10.5-59.1
EPS (diluted, $ a share)$-0.15$-0.85

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+190.2%
Operating margin-39.6%
Source

10-Q filed with the SEC, NASDAQ: BCYC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bicycle Therapeutics PLC: key numbers

Share price
$3.20Close, Nov 17
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bicycle Therapeutics PLC

All →
7:06 AM ET 8-K
Financial Results

Bicycle Therapeutics Financial Results

Bicycle Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $469.9 million and a runway extending into 2030. The company also announced that the FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer and plans to initiate its first company-sponsored radioligand clinical trial in 2H 2027.

“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands.”

Kevin Lee, Ph.D., Bicycle CEO

“We remain focused on disciplined execution across our prioritized programs and believe our growing clinical data continue to demonstrate the potential of Bicycle® molecules to deliver highly targeted therapies with differentiated benefit/risk profiles.”

Kevin Lee, Ph.D., Bicycle CEO
4:45 PM ET Form 4
Insider Selling

Bicycle Therapeutics Director Robert Charles Swanton Sells $11.9K of Stock

Robert Charles Swanton, Director, sold 3,431 shares of Bicycle Therapeutics PLC at $3.47 a share, worth $11.9K in total on Oct 2, 2026. Shares held after the trade: 15,782 (-17.9%).

Value
$11.9K
Shares
3,431
Price
$3.47
Role
Director
Holding change
-17.9%
Trade date
Oct 2, 2026
4:45 PM ET Form 4
Insider Selling

Bicycle Therapeutics CEO Kevin Lee Sells $21.4K of Stock

Kevin Lee, CEO, sold 6,167 shares of Bicycle Therapeutics PLC at $3.47 a share, worth $21.4K in total on Oct 2, 2026. Shares held after the trade: 597,504 (-1.0%).

Value
$21.4K
Shares
6,167
Price
$3.47
Role
CEO
Holding change
-1.0%
Trade date
Oct 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.